A Hydroalcoholic Extract from the Leaves of Nerium oleander
                    Inhibits Glycolysis and Induces Selective Killing of Lung Cancer
                    Cells

José Manuel Calderón-Montaño; Estefanía Burgos-Morón; Manuel Luis Orta; Santiago Mateos; Miguel López-Lázaro

doi:10.1055/s-0032-1328715

Planta Medica, Table of Contents

Planta Med 2013; 79(12): 1017-1023
DOI: 10.1055/s-0032-1328715

Biological and Pharmacological Activity

Original Papers

Georg Thieme Verlag KG Stuttgart · New York

A Hydroalcoholic Extract from the Leaves of Nerium oleander Inhibits Glycolysis and Induces Selective Killing of Lung Cancer Cells

José Manuel Calderón-Montaño

¹Department of Pharmacology, Faculty of Pharmacy, University of Seville, Seville, Spain

,

Estefanía Burgos-Morón

¹Department of Pharmacology, Faculty of Pharmacy, University of Seville, Seville, Spain

,

Manuel Luis Orta

²Department of Cell Biology, Faculty of Biology, University of Seville, Seville, Spain

,

Santiago Mateos

²Department of Cell Biology, Faculty of Biology, University of Seville, Seville, Spain

,

Miguel López-Lázaro

¹Department of Pharmacology, Faculty of Pharmacy, University of Seville, Seville, Spain

› Author Affiliations

Abstract

Recent evidence suggests that cardiac glycosides might be used for the treatment of cancer. The ornamental shrub Nerium oleander has been used in traditional medicine for treating several disorders including cancer, and extracts from the leaves of this plant have already entered phase I clinical trials. In this communication, we have prepared a hydroalcoholic extract from the leaves of Nerium oleander (containing 4.75 ± 0.32 % of cardenolides) and have assessed its cytotoxic activity in A549 lung cancer cells vs. MRC5 nonmalignant lung fibroblasts. The results showed that the cytotoxicity of the Nerium oleander extract against the cancer cell line was significantly higher than that against the nonmalignant cell line, with a potency and selectivity similar to those of the anticancer drug cisplatin. Pretreatment of A549 cells with the antioxidants N-acetylcysteine and catalase slightly prevented the cytotoxicity of the extract, therefore suggesting that the formation of reactive oxygen species participates in its cytotoxic activity but does not play a major role. Nerium oleander extract-induced cytotoxicity and DNA damage (gamma-H2AX focus formation) were slightly higher in cells lacking BRCA2 (deficient in homologous recombination repair) than in parental cells; this indicates that the induction of DNA damage may also play a role in the cytotoxicity of the extract. Nerium oleander extract induced a marked inhibition of glycolysis (glucose consumption and lactate production) in A549 cells, comparable to that of the glycolysis inhibitor dichloroacetate (currently in clinical development for cancer therapy). Because platinum compounds are widely used in the treatment of lung cancer, we tested the cytotoxicity of several combinations of cisplatin with the extract and found a moderate synergism when Nerium oleander extract was administered after cisplatin but a moderate antagonism when it was added before cisplatin. Our results suggest that extracts from Nerium oleander might induce anticancer effects in patients with lung cancer and support their possible advancement into phase II clinical trials for the treatment of this type of cancer.

Key words

Nerium oleander - Apocynaceae - cardiac glycosides - cardiotonic steroids - anticancer

Full Text

References

References
1 Rahimtoola SH, Tak T. The use of digitalis in heart failure. Curr Probl Cardiol 1996; 21: 781-853
2 Xie Z, Askari A. Na(+)/K(+)-ATPase as a signal transducer. Eur J Biochem 2002; 269: 2434-2439
3 Schoner W, Scheiner-Bobis G. Endogenous and exogenous cardiac glycosides: their roles in hypertension, salt metabolism, and cell growth. Am J Physiol Cell Physiol 2007; 293: C509-C536
4 Haux J. Digitoxin is a potential anticancer agent for several types of cancer. Med Hypotheses 1999; 53: 543-548
5 Lopez-Lazaro M. Digitoxin as an anticancer agent with selectivity for cancer cells: possible mechanisms involved. Expert Opin Ther Targets 2007; 11: 1043-1053
6 Newman RA, Yang P, Pawlus AD, Block KI. Cardiac glycosides as novel cancer therapeutic agents. Mol Interv 2008; 8: 36-49
7 Prassas I, Diamandis EP. Novel therapeutic applications of cardiac glycosides. Nat Rev Drug Discov 2008; 7: 926-935
8 Mijatovic T, Van Quaquebeke E, Delest B, Debeir O, Darro F, Kiss R. Cardiotonic steroids on the road to anti-cancer therapy. Biochim Biophys Acta 2007; 1776: 32-57
9 Sreenivasan Y, Raghavendra PB, Manna SK. Oleandrin-mediated expression of Fas potentiates apoptosis in tumor cells. J Clin Immunol 2006; 26: 308-322
10 Hallbook H, Felth J, Eriksson A, Fryknas M, Bohlin L, Larsson R, Gullbo J. Ex vivo activity of cardiac glycosides in acute leukaemia. PLoS One 2011; 6: e15718
11 Lopez-Lazaro M, Pastor N, Azrak SS, Ayuso MJ, Austin CA, Cortes F. Digitoxin inhibits the growth of cancer cell lines at concentrations commonly found in cardiac patients. J Nat Prod 2005; 68: 1642-1645
12 Mijatovic T, Op DB, Van Quaquebeke E, Dewelle J, Darro F, de Launoit Y, Kiss R. The cardenolide UNBS1450 is able to deactivate nuclear factor kappaB-mediated cytoprotective effects in human non-small cell lung cancer cells. Mol Cancer Ther 2006; 5: 391-399
13 Zhang H, Qian DZ, Tan YS, Lee K, Gao P, Ren YR, Rey S, Hammers H, Chang D, Pili R, Dang CV, Liu JO, Semenza GL. Digoxin and other cardiac glycosides inhibit HIF-1alpha synthesis and block tumor growth. Proc Natl Acad Sci USA 2008; 105: 19579-19586
14 Lopez-Lazaro M. Digoxin, HIF-1, and cancer. Proc Natl Acad Sci USA 2009; 106: E26
15 Rashan LJ, Franke K, Khine MM, Kelter G, Fiebig HH, Neumann J, Wessjohann LA. Characterization of the anticancer properties of monoglycosidic cardenolides isolated from Nerium oleander and Streptocaulon tomentosum . J Ethnopharmacol 2011; 134: 781-788
16 Mijatovic T, Kiss R. Cardiotonic steroids-mediated Na+/K+-ATPase targeting could circumvent various chemoresistance pathways. Planta Med 2013; 79: 189-198
17 Perne A, Muellner MK, Steinrueck M, Craig-Mueller N, Mayerhofer J, Schwarzinger I, Sloane M, Uras IZ, Hoermann G, Nijman SM, Mayerhofer M. Cardiac glycosides induce cell death in human cells by inhibiting general protein synthesis. PLoS One 2009; 4: e8292
18 Pelicano H, Martin DS, Xu RH, Huang P. Glycolysis inhibition for anticancer treatment. Oncogene 2006; 25: 4633-4646
19 Lopez-Lazaro M. The Warburg effect: why and how do cancer cells activate glycolysis in the presence of oxygen?. Anticancer Agents Med Chem 2008; 8: 305-312
20 Lopez-Lazaro M, Palma DLP, Pastor N, Martin-Cordero C, Navarro E, Cortes F, Ayuso MJ, Toro MV. Anti-tumour activity of Digitalis purpurea L. subsp. heywoodii . Planta Med 2003; 69: 701-704
21 Watters GP, Smart DJ, Harvey JS, Austin CA. H2AX phosphorylation as a genotoxicity endpoint. Mutat Res 2009; 679: 50-58
22 Lobrich M, Shibata A, Beucher A, Fisher A, Ensminger M, Goodarzi AA, Barton O, Jeggo PA. gammaH2AX foci analysis for monitoring DNA double-strand break repair: strengths, limitations and optimization. Cell Cycle 2010; 9: 662-669
23 Pastor N, Pinero J, Ortiz T, Mateos JC, De Miguel M, Cortes F. Topoisomerase activities and levels in irradiated Chinese hamster AA8 cells and in its radiosensitive mutant EM9. Int J Radiat Biol 1999; 75: 1035-1042
24 Cao X, Bloomston M, Zhang T, Frankel WL, Jia G, Wang B, Hall NC, Koch RM, Cheng H, Knopp MV, Sun D. Synergistic antipancreatic tumor effect by simultaneously targeting hypoxic cancer cells with HSP90 inhibitor and glycolysis inhibitor. Clin Cancer Res 2008; 14: 1831-1839
25 Mekhail T, Kaur H, Ganapathi R, Budd GT, Elson P, Bukowski RM. Phase 1 trial of Anvirzel in patients with refractory solid tumors. Invest New Drugs 2006; 24: 423-427
26 Henary HA, Kurzrock R, Falchook GS, Naing A, Moulder SL, Wheler JJ, Tsimberidou AM, Durand J, Yang P, Johansen MJ, Newman R, Khan R, Patel U, Hong DS. Final results of a first-in-human phase I trial of PBI-05204, an inhibitor of AKT, FGF-2, NF-Kb, and p 70S6K in advanced cancer patients. ASCO Meeting Abstracts 2011; 29: 3023
27 Lopez-Lazaro M, Calderon-Montano JM, Burgos-Moron E, Austin CA. Green tea constituents (−)-epigallocatechin-3-gallate (EGCG) and gallic acid induce topoisomerase I- and topoisomerase II-DNA complexes in cells mediated by pyrogallol-induced hydrogen peroxide. Mutagenesis 2011; 26: 489-498
28 Vega-Perez JM, Palo-Nieto C, Periñan I, Vega-Holm M, Calderon-Montano JM, Lopez-Lazaro M, Iglesias-Guerra F. Stereoselective dihydroxylation reaction of alkenyl β-D-hexopyranosides: a methodology for the synthesis of glycosylglycerol derivatives and 1-O-acyl-3-O-β-D-glycosyl-sn-glycerol analogues. Eur J Org Chem 2012; 6: 1237-1252
29 Alexandre J, Batteux F, Nicco C, Chereau C, Laurent A, Guillevin L, Weill B, Goldwasser F. Accumulation of hydrogen peroxide is an early and crucial step for paclitaxel-induced cancer cell death both in vitro and in vivo . Int J Cancer 2006; 119: 41-48
30 Lopez-Lazaro M. Dual role of hydrogen peroxide in cancer: Possible relevance to cancer chemoprevention and therapy. Cancer Lett 2007; 252: 1-8
31 Lopez-Lazaro M. A new view of carcinogenesis and an alternative approach to cancer therapy. Mol Med 2010; 16: 144-153
32 Martin-Cordero C, Leon-Gonzalez AJ, Calderon-Montano JM, Burgos-Moron E, Lopez-Lazaro M. Pro-oxidant natural products as anticancer agents. Curr Drug Targets 2012; 13: 1006-1028
33 Newman RA, Yang P, Hittelman WN, Lu T, Ho DH, Ni D, Chan D, Vijjeswarapu M, Cartwright C, Dixon S, Felix E, Addington C. Oleandrin-mediated oxidative stress in human melanoma cells. J Exp Ther Oncol 2006; 5: 167-181
34 Helleday T, Petermann E, Lundin C, Hodgson B, Sharma RA. DNA repair pathways as targets for cancer therapy. Nat Rev Cancer 2008; 8: 193-204
35 Lord CJ, Ashworth A. The DNA damage response and cancer therapy. Nature 2012; 481: 287-294
36 Postel-Vinay S, Vanhecke E, Olaussen KA, Lord CJ, Ashworth A, Soria JC. The potential of exploiting DNA-repair defects for optimizing lung cancer treatment. Nat Rev Clin Oncol 2012; 9: 144-155
37 Bielawski K, Winnicka K, Bielawska A. Inhibition of DNA topoisomerases I and II, and growth inhibition of breast cancer MCF-7 cells by ouabain, digoxin and proscillaridin A. Biol Pharm Bull 2006; 29: 1493-1497
38 Jornada LK, Valvassori SS, Arent CO, Leffa D, Damiani AA, Hainzenreder G, Ferreira CL, Moretti M, Andrade VM, Quevedo J. DNA damage after intracerebroventricular injection of ouabain in rats. Neurosci Lett 2010; 471: 6-9
39 Hiyoshi H, Abdelhady S, Segerstrom L, Sveinbjornsson B, Nuriya M, Lundgren TK, Desfrere L, Miyakawa A, Yasui M, Kogner P, Johnsen JI, Andang M, Uhlen P. Quiescence and gammaH2AX in neuroblastoma are regulated by ouabain/Na,K-ATPase. Br J Cancer 2012; 106: 1807-1815
40 Gupta RS, Chopra A, Stetsko DK. Cellular basis for the species differences in sensitivity to cardiac glycosides (digitalis). J Cell Physiol 1986; 127: 197-206
41 Paul RJ, Bauer M, Pease W. Vascular smooth muscle: aerobic glycolysis linked to sodium and potassium transport processes. Science 1979; 206: 1414-1416
42 James JH, Fang CH, Schrantz SJ, Hasselgren PO, Paul RJ, Fischer JE. Linkage of aerobic glycolysis to sodium-potassium transport in rat skeletal muscle. Implications for increased muscle lactate production in sepsis. J Clin Invest 1996; 98: 2388-2397
43 Ishikawa N, Oguri T, Isobe T, Fujitaka K, Kohno N. SGLT gene expression in primary lung cancers and their metastatic lesions. Jpn J Cancer Res 2001; 92: 874-879
44 Yang P, Menter DG, Cartwright C, Chan D, Dixon S, Suraokar M, Mendoza G, Llansa N, Newman RA. Oleandrin-mediated inhibition of human tumor cell proliferation: importance of Na,K-ATPase alpha subunits as drug targets. Mol Cancer Ther 2009; 8: 2319-2328
45 Mijatovic T, Roland I, Van Quaquebeke E, Nilsson B, Mathieu A, Van Vynckt F, Darro F, Blanco G, Facchini V, Kiss R. The alpha1 subunit of the sodium pump could represent a novel target to combat non-small cell lung cancers. J Pathol 2007; 212: 170-179
46 Yang P, Cartwright C, Efuet E, Hamilton SR, Wistuba II, Menter D, Addington C, Shureiqi I, Newman RA. Cellular location and expression of Na(+), K(+) -ATPase alpha subunits affect the anti-proliferative activity of oleandrin. Mol Carcinogen advance online publication 16 Oct 2012
47 Chou TC. Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res 2010; 70: 440-446
48 Kishimoto S, Kawazoe Y, Ikeno M, Saitoh M, Nakano Y, Nishi Y, Fukushima S, Takeuchi Y. Role of Na+, K+-ATPase alpha1 subunit in the intracellular accumulation of cisplatin. Cancer Chemother Pharmacol 2006; 57: 84-90
49 Mijatovic T, Dufrasne F, Kiss R. Cardiotonic steroids-mediated targeting of the Na(+)/K(+)-ATPase to combat chemoresistant cancers. Curr Med Chem 2012; 19: 627-646